JP2017526361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526361A5 JP2017526361A5 JP2017511182A JP2017511182A JP2017526361A5 JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5 JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5
- Authority
- JP
- Japan
- Prior art keywords
- signaling
- domain
- binding domain
- car
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011664 signaling Effects 0.000 claims description 59
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 46
- 108020003175 receptors Proteins 0.000 claims description 34
- 102000005962 receptors Human genes 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 210000000822 natural killer cell Anatomy 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002588 toxic effect Effects 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 6
- 108010021152 pepBs1-Ac peptide Proteins 0.000 claims description 6
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102000009661 Repressor Proteins Human genes 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 229960004023 minocycline Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 230000002411 adverse Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1415347.2A GB201415347D0 (en) | 2014-08-29 | 2014-08-29 | Signalling system |
| GB1415347.2 | 2014-08-29 | ||
| PCT/GB2015/052494 WO2016030691A1 (en) | 2014-08-29 | 2015-08-28 | Signalling system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526361A JP2017526361A (ja) | 2017-09-14 |
| JP2017526361A5 true JP2017526361A5 (enExample) | 2018-08-09 |
| JP6614619B2 JP6614619B2 (ja) | 2019-12-04 |
Family
ID=51752358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511182A Active JP6614619B2 (ja) | 2014-08-29 | 2015-08-28 | シグナル伝達系 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10654927B2 (enExample) |
| EP (2) | EP3981417A1 (enExample) |
| JP (1) | JP6614619B2 (enExample) |
| KR (1) | KR102222615B1 (enExample) |
| CN (1) | CN106573989B (enExample) |
| AU (1) | AU2015308243B2 (enExample) |
| BR (1) | BR112017003906A2 (enExample) |
| CA (1) | CA2955668A1 (enExample) |
| CL (1) | CL2017000438A1 (enExample) |
| ES (1) | ES2910008T3 (enExample) |
| GB (1) | GB201415347D0 (enExample) |
| IL (1) | IL250101B (enExample) |
| MX (1) | MX376613B (enExample) |
| NZ (1) | NZ728674A (enExample) |
| RU (1) | RU2731638C2 (enExample) |
| SG (1) | SG11201700171VA (enExample) |
| WO (1) | WO2016030691A1 (enExample) |
| ZA (1) | ZA201700466B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| MY178233A (en) | 2013-12-20 | 2020-10-07 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| US11827904B2 (en) * | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| GB201602571D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201602563D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2018009923A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| GB201610515D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| EP3538556A1 (en) | 2016-11-11 | 2019-09-18 | Autolus Limited | Chimeric antigen receptor |
| WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201621891D0 (en) * | 2016-12-21 | 2017-02-01 | Autolus Ltd | Transcription system |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP7270253B2 (ja) | 2017-03-27 | 2023-05-10 | ナショナル ユニヴァーシティ オブ シンガポール | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 |
| CA3062727A1 (en) * | 2017-05-15 | 2018-11-22 | Autolus Limited | A cell comprising a chimeric antigen receptor (car) |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| GB201709508D0 (en) * | 2017-06-15 | 2017-08-02 | Autolus Ltd | Chimeric antigen receptor |
| CN111164203A (zh) * | 2017-08-02 | 2020-05-15 | 奥托路斯有限公司 | 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞 |
| CN107475276A (zh) * | 2017-09-05 | 2017-12-15 | 深圳大学 | 嵌合抗原受体及其表达基因、四环素调节的嵌合抗原受体修饰的t细胞及其应用 |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| WO2019155288A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| GB201805918D0 (en) * | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| WO2019197676A1 (en) | 2018-04-13 | 2019-10-17 | Ludwig Institute For Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| GB201807693D0 (en) | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| JP7335272B2 (ja) | 2018-05-15 | 2023-08-29 | オートラス リミテッド | キメラ抗原受容体 |
| GB201813178D0 (en) | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| CN119119296A (zh) * | 2018-09-05 | 2024-12-13 | 波赛达治疗公司 | 同种异体细胞组合物和使用方法 |
| DK3856775T3 (da) | 2018-09-27 | 2025-02-03 | Autolus Ltd | Kimær antigenreceptor |
| GB201816839D0 (en) * | 2018-10-16 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Novel control switch |
| BR112021017537A2 (pt) | 2019-03-05 | 2021-12-14 | Nkarta Inc | Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia |
| US20220145325A1 (en) | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| GB201906202D0 (en) | 2019-05-02 | 2019-06-19 | Autolus Ltd | Cell |
| US20220257757A1 (en) | 2019-07-16 | 2022-08-18 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
| GB201913258D0 (en) | 2019-09-13 | 2019-10-30 | Autolus Ltd | Antigen-binding domain |
| GB201919019D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| WO2021205175A1 (en) | 2020-04-09 | 2021-10-14 | Autolus Limited | Molecule |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| GB202017343D0 (en) | 2020-11-02 | 2020-12-16 | Autolus Ltd | Cell |
| GB202104030D0 (en) | 2021-03-23 | 2021-05-05 | Autolus Ltd | Signalling system |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| GB202219568D0 (en) | 2022-12-22 | 2023-02-08 | Autolus Ltd | Chimeric antigen receptor |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011100566A2 (en) * | 2010-02-12 | 2011-08-18 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| AU2014216130B2 (en) * | 2013-02-15 | 2017-11-16 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
| RS63798B1 (sr) | 2013-05-13 | 2022-12-30 | Cellectis | Cd19 specifični himerni antigenski receptor i njegove primene |
| PL3071223T3 (pl) * | 2013-11-21 | 2021-08-16 | Autolus Limited | Komórka |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| US9791929B2 (en) * | 2014-10-31 | 2017-10-17 | Elwha Llc | Tactile control system |
| KR20200003939A (ko) * | 2014-12-24 | 2020-01-10 | 유씨엘 비즈니스 리미티드 | 세포 |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| AU2017207284B2 (en) * | 2016-01-11 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric proteins and methods of regulating gene expression |
| GB201602563D0 (en) | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201602571D0 (en) | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
-
2014
- 2014-08-29 GB GBGB1415347.2A patent/GB201415347D0/en not_active Ceased
-
2015
- 2015-08-28 CN CN201580045056.1A patent/CN106573989B/zh active Active
- 2015-08-28 KR KR1020177007191A patent/KR102222615B1/ko not_active Expired - Fee Related
- 2015-08-28 EP EP21193028.4A patent/EP3981417A1/en not_active Withdrawn
- 2015-08-28 WO PCT/GB2015/052494 patent/WO2016030691A1/en not_active Ceased
- 2015-08-28 MX MX2017000616A patent/MX376613B/es active IP Right Grant
- 2015-08-28 ES ES15757558T patent/ES2910008T3/es active Active
- 2015-08-28 JP JP2017511182A patent/JP6614619B2/ja active Active
- 2015-08-28 BR BR112017003906-0A patent/BR112017003906A2/pt not_active IP Right Cessation
- 2015-08-28 US US15/506,383 patent/US10654927B2/en active Active
- 2015-08-28 CA CA2955668A patent/CA2955668A1/en not_active Abandoned
- 2015-08-28 AU AU2015308243A patent/AU2015308243B2/en not_active Ceased
- 2015-08-28 SG SG11201700171VA patent/SG11201700171VA/en unknown
- 2015-08-28 RU RU2017105515A patent/RU2731638C2/ru active
- 2015-08-28 NZ NZ728674A patent/NZ728674A/en not_active IP Right Cessation
- 2015-08-28 EP EP15757558.0A patent/EP3185875B1/en active Active
-
2017
- 2017-01-15 IL IL250101A patent/IL250101B/en active IP Right Grant
- 2017-01-19 ZA ZA2017/00466A patent/ZA201700466B/en unknown
- 2017-02-23 CL CL2017000438A patent/CL2017000438A1/es unknown
-
2020
- 2020-04-14 US US16/848,717 patent/US20210032332A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526361A5 (enExample) | ||
| Kamiya et al. | Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells | |
| RU2017105515A (ru) | Сигнальная система | |
| JP7068459B2 (ja) | Nyeso tcr | |
| Zhao et al. | Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential | |
| Jamieson et al. | The role of the NKG2D immunoreceptor in immune cell activation and natural killing | |
| Dargel et al. | T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice | |
| JP2021036913A (ja) | 細胞 | |
| Zhang et al. | Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody | |
| JP2016538855A5 (enExample) | ||
| JP2019530431A5 (enExample) | ||
| RU2016124278A (ru) | Клетка | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| BR112021007626A2 (pt) | Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d) | |
| KR20240063204A (ko) | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 | |
| CN114616244A (zh) | 特异性结合mage-a的抗原结合蛋白 | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2019535262A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2021503006A5 (enExample) | ||
| WO2017130223A3 (en) | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof | |
| JP2017513478A5 (enExample) | ||
| JP2020512973A5 (enExample) | ||
| US20230149460A1 (en) | Methods for generating engineered memory-like nk cells and compositions thereof | |
| JP2020501512A5 (enExample) |